Single daily ciclosporin (Neoral®) administration before breakfast for psoriasis treatment

Ryuhei Okuyama, Eisaku Ogawa, Tomoyuki Ohtani, Maki Ozawa, Setsuya Aiba

Research output: Contribution to journalArticlepeer-review

Abstract

We studied low doses of Ciclosporin for short-term treatment in 26 patients with psoriasis vulgaris. The microemulsion form of Ciclosporin was given once under fasting conditions every morning at a dose of 2.0-2.5 mg/body weight daily. This dose was maintained for a maximum of 12 weeks, and it was reduced gradually. PASI (Psoriasis Area and Severity Index) was assessed for its efficacy. Within the 12 weeks, 75% or more improvement in PASI was achieved in 62.5% of the patients, with more than 50% improvement in 91.7%. Hypertension occurred in 2 cases during the study, but the serum creatinine concentration and liver function did not show any clinically significant changes. Our results show that low dose, short term therapy with Ciclosporin provides effective control of psoriasis without severe toxicity. In addition, although tapering off Ciclosporin induces psoriasis relapse in 9 cases among 14 cases, topical therapy maintained the improvement even after the cessation of Ciclosporin in other 5 cases. Such a different effect after the administration is clinically interesting, and therapies are still necessary for suppressing the relapse.

Original languageEnglish
Pages (from-to)670-675
Number of pages6
JournalNishinihon Journal of Dermatology
Volume69
Issue number6
DOIs
Publication statusPublished - 2007

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Single daily ciclosporin (Neoral®) administration before breakfast for psoriasis treatment'. Together they form a unique fingerprint.

Cite this